SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Adolor ADLR
An SI Board Since April 2002
Posts SubjectMarks Bans Symbol
2 1 0 ADLR
Emcee:  Jack Hartmann Type:  Moderated
Introduction Market Data Compact
Adolor Corporation is a therapeutic-based biopharmaceutical company. The Company discovers, develops and plans to commercialize proprietary pharmaceutical products for the treatment of pain and the side effects that are caused by pain treatments. The Company has a portfolio of small-molecule product candidates that are in various stages of development, ranging from preclinical studies to Phase I through Phase II/III clinical trials. The Company's lead product candidate, ADL 8-2698, is designed to selectively block the effects of narcotic analgesics on the gastrointestinal (GI) tract. ADL 8-2698 is a peripherally acting, GI tract-restricted mu opioid receptor antagonist that is designed to block the adverse side effects of narcotic analgesics on the GI tract without blocking their beneficial analgesic effects.
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News